Product Center
Ab&B Bio-Tech Co., Ltd. JS Has Developed the World's First Broad-Spectrum mRNA Vaccine Against Smallpox Virus
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-05-08
- Views:
(Summary description)Since May 2022, the global monkeypox epidemic has drawn public attention to the threat of human-to-human transmission of zoonotic diseases. In July 2022, the World Health Organization declared the monkeypox outbreak a Public Health Emergency of International Concern (PHEIC). The academic community and pharmaceutical companies have been actively proposing various prevention and control strategies, including accelerating vaccine research and development.
Ab&B Bio-Tech Co., Ltd. JS Has Developed the World's First Broad-Spectrum mRNA Vaccine Against Smallpox Virus
(Summary description)Since May 2022, the global monkeypox epidemic has drawn public attention to the threat of human-to-human transmission of zoonotic diseases. In July 2022, the World Health Organization declared the monkeypox outbreak a Public Health Emergency of International Concern (PHEIC). The academic community and pharmaceutical companies have been actively proposing various prevention and control strategies, including accelerating vaccine research and development.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-05-08 11:30
- Views:
Since May 2022, the global monkeypox epidemic has drawn public attention to the threat of human-to-human transmission of zoonotic diseases. In July 2022, the World Health Organization declared the monkeypox outbreak a Public Health Emergency of International Concern (PHEIC). The academic community and pharmaceutical companies have been actively proposing various prevention and control strategies, including accelerating vaccine research and development.
On April 26, 2023, Dr. Xiong Yelin (Vice President) and Dr. Liu Zhihua (Project Director) of Yither Biotech Co., Ltd., a wholly-owned subsidiary of Ab&B Bio-Tech Co., Ltd. JS, announced their company's research progress on the broad-spectrum mRNA vaccine for smallpox virus on bioRxiv: "A Quadrivalent mRNA Immunization Elicits Potent Immune Responses Against Vaccinia and Monkeypox Viral Antigens – A Step Closer to a Broad Orthopoxvirus Vaccine".
The R&D team found through preliminary research that, in addition to monkeypox virus, other poxviruses, including cowpox and camelpox virus, are also infectious and pathogenic to humans, with potential risks of smallpox virus release through bioterrorism or laboratory accidents.
The morphologies of vaccinia virus, smallpox virus, monkeypox virus, camelpox virus, sheep pox virus, and cowpox virus are similar, and they share antigenic relationships. Among them, A27, A33, B5, and L1 proteins, which are involved in viral adsorption, binding, and intercellular transmission, are highly conserved among orthopoxviruses. This explains the immunological basis for the success of live-attenuated poxvirus vaccines in preventing smallpox last century. Antibody studies show these proteins contain numerous broad-spectrum neutralizing epitopes, making them ideal candidate antigens for broad-spectrum vaccines.
Based on this pathobiological and vaccinological foundation, the team designed original tandem constructs of vaccinia virus surface antigens A27, A33, B5, and L1 to form a single mRNA molecule. Through their mRNA-LNP delivery platform, they developed the world's first quadrivalent broad-spectrum mRNA candidate vaccine (mRNA-ALAB) against orthopoxviruses.
While inducing potent immune responses, the mRNA vaccine showed no safety concerns in animal studies, eliminating the severe side effects associated with traditional live-attenuated smallpox vaccines. Regarding molecular design, compared to co-delivery of multiple mRNA molecules, the company's innovative single-mRNA multi-antigen delivery system significantly simplifies manufacturing processes, reduces development timelines, and offers cost advantages in production. This approach provides a practical vaccine strategy for responding to large-scale outbreaks.
Moving forward, the R&D team will further investigate the vaccine's broad-spectrum efficacy and functional characteristics.Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
